ASH 2024 Summary: MPN Highlights and Clinical Implications

2024 ASH Annual Meeting Insights Hub

D. Tremblay

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How

2024 ASH Annual Meeting Insights Hub

J. Kiladjian

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

Momelotinib in MF: Insights from SIMPLIFY-1, SIMPLIFY-2, and MOMENTU…

Jeanne Palmer

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Myelofibrosis: Diagnosis, Clinical Manifestations, Treatment Approac…

Amy Zhou

Allele Burden in MPN: Practical Considerations

16th International Congress on Myeloproliferative Neoplasms

R. Rampal

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Rux…

2024 ASH Annual Meeting Insights Hub

J. Mascarenhas

Novel Agents for MPNs in 2024

16th International Congress on Myeloproliferative Neoplasms

N. Pemmaraju

Current and Future Treatment Landscape of Myelofibrosis

XV Eurasian Hematology-Oncology Congress - EHOC 2024

R. Komrokji

Overview of Myelofibrosis: Management, JAK Inhibitor Trials, and Eme…

Akhil Jain

COMFORT-1 Trial Long-Term Follow-Up: Impact of Ruxolitinib on OS for…

Winship Cancer Institute - Emory University

A. Hunter

Treatment Landscape of JAK Inhibitors in Myelofibrosis

Juliana Schwaab